Case of simultaneous occurrence of hepatitis, cholangitis, and pancreatitis as immune-related adverse events induced by immune checkpoint inhibitor therapy: a case report

Kohei Kawata, Dai Inoue, Takahiro Komori, Takashi Matsubara, Fumihito Toshima, Kazuto Kozaka, Masahiro Yanagi, Hiroko Ikeda, Satoshi KobayashiAbdominal 2025 · DOI

Abstract

As the use of immune checkpoint inhibitors (ICIs) expands in oncology, clinicians are encountering a wider array of immune-related adverse events (irAEs). While single-organ inflammation is common, concurrent multi-organ involvement is rare and presents significant diagnostic challenges. This report details a unique case of a patient in his 80s who developed simultaneous hepatitis, cholangitis, and pancreatitis following pembrolizumab therapy for renal pelvic cancer. The case highlights the importance of recognizing multi-organ irAE patterns on imaging to ensure timely diagnosis and management.

Introduction

Immune checkpoint inhibitors have revolutionized cancer treatment by enhancing the immune system's ability to target malignant cells. However, this systemic activation can lead to "friendly fire" in the form of immune-related adverse events (irAEs). While irAEs commonly affect the skin, colon, or lungs, simultaneous inflammation of the liver, bile ducts, and pancreas is exceptionally rare. This "triple threat" of digestive organ inflammation can mimic other autoimmune conditions or infections, potentially leading to delayed treatment.

Case Presentation

A man in his 80s, undergoing pembrolizumab treatment for recurrent renal pelvic cancer, presented with a loss of appetite. Initial laboratory results showed significant elevations in inflammatory markers and liver enzymes (AST: 942 IU/L, ALP: 2081 IU/L). Pancreatic enzymes were also elevated (Amylase: 528 IU/L).

Initial non-contrast CT suggested cholecystitis and cholangitis. However, when symptoms failed to improve with antibiotics, advanced imaging was performed to reassess the underlying cause.

Diagnostic Findings

Contrast-enhanced dynamic CT and gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid-enhanced MRI (EOB-MRI) provided critical insights. The imaging revealed not only bile duct wall thickening and edematous changes along Glisson's sheath—suggestive of cholangitis—but also inflammatory enlargement in the pancreatic tail.

Multi-slice CT imaging showing inflammatory changes in the liver, bile ducts, and pancreas.

A liver biopsy was performed to confirm the diagnosis. Histopathological analysis showed significant T-cell infiltration, specifically CD3(+) cells with a predominance of CD8(+) "killer" T cells, confirming that the inflammation was a direct result of the ICI's effect on T-cell regulation. This led to a final diagnosis of concurrent hepatitis, cholangitis, and pancreatitis as irAEs.

Discussion

The imaging findings for irAE cholangitis often mimic primary sclerosing cholangitis (PSC) or IgG4-related cholangitis. However, the simultaneous presence of pancreatitis in a patient receiving immunotherapy should strongly point toward an irAE.

A key clinical takeaway from this case is the differential response to treatment. While irAE hepatitis typically responds well to corticosteroids, irAE cholangitis is notably more resistant, with literature suggesting a steroid response rate of only approximately 11.5%. In this patient, high-dose prednisolone (60 mg/day) successfully normalized enzyme levels and resolved the imaging abnormalities, though the patient eventually succumbed to the progression of his primary cancer nine months later.

Conclusion

This case underscores the necessity for clinicians to maintain a high index of suspicion for multi-organ irAEs in patients treated with ICIs. Recognizing the imaging "signature" of concurrent bile duct and pancreatic inflammation can be the clue needed to distinguish irAEs from more common biliary conditions. Early identification and the initiation of immunosuppressive therapy are vital to managing these complex systemic responses.

Summary updated

Abstract

The use of immune checkpoint inhibitors has increased in the field of oncology; however, various immune-related adverse events affecting multiple organs have been reported. Herein, we present a case of concurrent hepatitis, cholangitis, and pancreatitis as immune-related adverse events (irAE); a case of autoimmune disease due to oncologic immunotherapy. A man in his 80s who was undergoing pembrolizumab therapy for recurrent renal pelvic cancer presented to the emergency department with a loss of appetite. Laboratory tests revealed elevated levels of inflammatory markers and liver enzymes. Initial non-contrast computed tomography (CT) suggested cholecystitis and cholangitis, for which antibiotics were administered. However, because of poor improvement, contrast-enhanced dynamic CT and gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid-enhanced magnetic resonance imaging (MRI) were performed two weeks after visiting the emergency department to reassess the underlying cause. In these examinations, besides the bile dust wall thickening and edematous changes along Glisson's sheath suggesting the cholangitis, inflammatory enlargement in pancreatic tail was also revealed. Considering these imaging findings suggesting the cholangitis and pancreatitis during pembrolizumab therapy, irAE was suspected as the cause of symptoms. A liver biopsy subsequently performed strongly indicated hepatitis and cholangitis as irAE. Based on these findings, concurrent hepatitis, cholangitis, and pancreatitis as irAE by pembrolizumab were diagnosed. Imaging findings of irAE cholangitis are similar to those of primary sclerosing cholangitis and IgG4-related cholangitis. Particularly in cases like this one, where pancreatitis is also present. However, if a history of immune checkpoint inhibitor use is known, it is possible to include irAE in the differential diagnosis, as observed in this case. Therefore, by keeping the use of immune checkpoint inhibitors in mind during imaging interpretation, imaging examinations could be a clue to suggest the possibility of irAE. Recognizing the imaging findings associated with irAEs and the existence of cases where irAE cholangitis and irAE pancreatitis coexist, it can aid earlier diagnosis of irAEs.
BibTeX
@inproceedings{kawata2025case,
  author = {Kohei Kawata and Dai Inoue and Takahiro Komori and Takashi Matsubara and Fumihito Toshima and Kazuto Kozaka and Masahiro Yanagi and Hiroko Ikeda and Satoshi Kobayashi},
  title = {{Case of simultaneous occurrence of hepatitis, cholangitis, and pancreatitis as immune-related adverse events induced by immune checkpoint inhibitor therapy: a case report}},
  booktitle = {Abdominal},
  year = {2025},
  doi = {10.1007/s00261-025-04994-w},
}
Figure